[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642338":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":32,"studyPopulation":33,"armGroups":34,"interventions":20,"overallOfficials":38,"centralContacts":42,"locations":20,"responsibleParty":48,"collaborators":20,"id":50,"slug":20,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":20,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":20,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":68,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":20},{"fullName":5,"class":6},"The First Affiliated Hospital of Guangzhou Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Change in percentage from baseline in peripheral blood CyTOF-defined immune phenotype parameters","Change in percentage of major immune-cell lineages and predefined T-cell differentiation\u002Fsenescence\u002Factivation\u002Fexhaustion parameters, including CD4+ T cells, CD8+ T cells, B cells, NK cells, Naive\u002FTCM\u002FTEM\u002FTEMRA subsets, CD57-related phenotypes, HLA-DR\u002FCD38 activation markers, and PD-1\u002FCTLA-4\u002FTIM-3\u002FTIGIT-related checkpoint expression, reported as percentages of parent populations and\u002For marker-positive frequencies.","Baseline and routine follow-up visits through 24 months",[14,18,22,25,27],{"measure":15,"description":16,"timeFrame":17},"Percentage of participants with pulmonary nodule evolution events assessed by routine chest CT","percentage of participants with postoperative residual or new pulmonary nodule evolution, including stable disease, nodule enlargement, new nodule development, increase in solid component, imaging risk upgrade, repeat biopsy, or repeat surgery, as recorded in routine clinical imaging and medical records.","Baseline through 24 months",{"measure":19,"description":20,"timeFrame":21},"Blood draw-related adverse events",null,"At each research blood collection visit from baseline through 24 months",{"measure":23,"description":20,"timeFrame":24},"Percentage of participants with positive CMV IgG measured by institutional immunoassay","Baseline",{"measure":26,"description":20,"timeFrame":17},"CyTOF assay completion rate",{"measure":28,"description":20,"timeFrame":17},"Research blood collection completion rate",{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":30,"timePerspective":31,"maskingInfo":20},"COHORT","PROSPECTIVE","The study is designed as a multicenter, prospective, non-randomized observational cohort. Eligible participants will be identified in thoracic surgery clinics, inpatient services, or routine postoperative follow-up programs at participating centers. After written informed consent, research blood samples of no more than 10 mL per time point will be collected together with routine clinical blood draws when available. No additional clinic visit, imaging examination, treatment, surgery, drug, device, vaccination, or other clinical intervention will be scheduled for research purposes. Peripheral blood will be analyzed using CyTOF mass cytometry to characterize major T-cell, B-cell, and NK-cell lineages, T-cell Naive\u002FTCM\u002FTEM\u002FTEMRA differentiation, CD57-related senescence, activation markers, and immune checkpoint\u002Fexhaustion-related markers. Viral imprinting-related serology may include CMV IgG, EBV VCA-IgG, EBV EBNA-IgG, HPV L1-related antibodies, or other tests available within the approved institutional laboratory scope. Clinical and exposure data will be abstracted from routine records and study CRFs, including demographics, smoking and exposure history, relevant comorbidities, pulmonary nodule characteristics, pathology, imaging follow-up, and subsequent biopsy or surgery. Analyses will describe longitudinal immune phenotypes and evaluate exploratory associations between immune reserve, immune senescence, viral imprinting markers, and pulmonary nodule stability, enlargement, new nodule development, imaging risk upgrade, repeat biopsy, or repeat surgery. All research assay results are for group-level research only and will not be used to guide individual diagnosis, treatment, imaging interval, medication, or surgical decisions.","Adults who have undergone surgical resection of a primary pulmonary nodule and have residual multiple pulmonary nodules or require routine postoperative pulmonary nodule follow-up at participating centers. Participants will be identified from thoracic surgery clinics, inpatient services, and routine postoperative follow-up programs. Eligible participants will provide written informed consent and will be followed according to usual clinical care; research blood samples and study data will be collected at clinically scheduled visits when routine blood draws and follow-up data are available.",[35],{"label":36,"type":20,"description":37,"interventionNames":20},"Postoperative Multiple Pulmonary Nodule Cohort","Adults with a resected primary pulmonary nodule who have residual multiple pulmonary nodules or require pulmonary nodule-related routine postoperative follow-up at participating centers. Participants will be followed according to routine clinical care, and research samples\u002Fdata will be collected at clinically scheduled visits.",[39],{"name":40,"affiliation":5,"role":41},"Jianxing","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":20,"email":47},"Jianxing He","CONTACT","020-83062810","jianxinghe@gzhmu.edu.cn",{"type":41,"investigatorFullName":44,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator","100642338",false,"NCT07647484","Peripheral Blood CyTOF and Viral Imprinting in Postoperative Multiple Pulmonary Nodules","A Multicenter Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules","Inclusion Criteria:\n\nAge 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.\n\nPlanned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.\n\nAble to understand the study and willing to provide written informed consent before research blood sample collection.\n\nExclusion Criteria:\n\nInvestigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.\n\nAcute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.\n\nCurrent strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.\n\nUnable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.\n\nAny other condition that, in the investigator's judgment, makes participation inappropriate.","ALL","18 Years",{"count":59,"type":60},200,"ESTIMATED","200 Months","OBSERVATIONAL","This multicenter prospective cohort study will enroll adults who have undergone resection of a primary pulmonary nodule and have residual multiple pulmonary nodules or require routine postoperative pulmonary nodule follow-up. During clinically indicated follow-up visits, a small amount of peripheral venous blood will be collected at the same time as routine blood draws for research CyTOF immune phenotyping and viral imprinting-related serology. The study will not assign participants to treatment, change follow-up schedules, imaging, medication, surgery, or other clinical care. Research laboratory results will not be returned to participants or entered into medical records. The study will describe longitudinal peripheral immune-cell profiles and explore associations among T\u002FB\u002FNK cell phenotypes, T-cell differentiation and senescence\u002Fexhaustion markers, viral imprinting markers, and postoperative residual or new pulmonary nodule evolution.",[65],"Multiple Pulmonary Nodules",[67],"CyTOF","NOT_YET_RECRUITING","2026-06-12",{"date":71,"type":72},"2026-06-15","ACTUAL",{"date":74,"type":60},"2026-07",{"date":76,"type":60},"2028-12",{"name":5,"class":6}]